UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 631

Sortiert nach

Dynamical System Modulation for Robot Learning via Kinesthetic Demonstrations

IEEE transactions on robotics, 2008-12, Vol.24 (6), p.1463-1467

2008

Volltextzugriff (PDF)

Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

The Journal of neuroscience, 2003-10, Vol.23 (28), p.9418-9427

2003

Volltextzugriff (PDF)

Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity

Brain (London, England : 1878), 2008-04, Vol.131 (4), p.1057-1068

2008

Volltextzugriff (PDF)

Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease

Science (American Association for the Advancement of Science), 2002-06, Vol.296 (5576), p.2238-2243

2002

Volltextzugriff (PDF)

Genome-Wide Expression Profiling of Human Blood Reveals Biomarkers for Huntington's Disease

Proceedings of the National Academy of Sciences - PNAS, 2005-08, Vol.102 (31), p.11023-11028

2005

Volltextzugriff (PDF)

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease

Neurology, 2014-03, Vol.82 (10), p.850

2014

Volltextzugriff (PDF)

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Nature medicine, 2000-07, Vol.6 (7), p.797-801

2000

Volltextzugriff (PDF)

Adhesive arachnoiditis following inadvertent epidural injection of 2% chlorhexidine in 70% alcohol - partial recovery over the ensuing eight years

Anaesthesia and intensive care, 2018-11, Vol.46 (6), p.572-574

2018

Volltextzugriff (PDF)

Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease

The Journal of neuroscience, 2002-10, Vol.22 (20), p.8942-8950

2002

Volltextzugriff (PDF)

Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease

The Journal of neuroscience, 2002-09, Vol.22 (18), p.7862-7872

2002

Volltextzugriff (PDF)

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse

Proceedings of the National Academy of Sciences - PNAS, 2011-10, Vol.108 (41), p.17141-17146

2011

Volltextzugriff (PDF)

Impaired Cerebrovascular Reactivity in Huntington's Disease

Frontiers in physiology, 2021-07, Vol.12, p.663898-663898

2021

Volltextzugriff (PDF)

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG

Neurology, 2006-01, Vol.66 (2), p.250

2006

Volltextzugriff (PDF)

Nuclear and Neuropil Aggregates in Huntington's Disease: Relationship to Neuropathology

The Journal of neuroscience, 1999-04, Vol.19 (7), p.2522-2534

1999

Volltextzugriff (PDF)

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients

Proceedings of the National Academy of Sciences - PNAS, 2017-06, Vol.114 (23), p.E4676-E4685

2017

Volltextzugriff (PDF)

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

The Journal of neuroscience, 2000-06, Vol.20 (12), p.4389-4397

2000

Volltextzugriff (PDF)

Cysteine Oxidation within N-terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein

The Journal of biological chemistry, 2011-05, Vol.286 (20), p.18320-18330

2011

Volltextzugriff (PDF)

The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease

Journal of personalized medicine, 2022-09, Vol.12 (10), p.1561

2022

Volltextzugriff (PDF)

Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease

Neurobiology of disease, 2001-06, Vol.8 (3), p.479-491

2001

Volltextzugriff (PDF)

A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration

Neuron (Cambridge, Mass.), 1999-05, Vol.23 (1), p.181-192

1999

Volltextzugriff (PDF)

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

Journal of neurochemistry, 2003-06, Vol.85 (6), p.1359-1367

2003

Volltextzugriff (PDF)

The CREST-E study of creatine for Huntington disease: A randomized controlled trial

Neurology, 2017-08, Vol.89 (6), p.594

2017

Volltextzugriff (PDF)

Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation

Journal of neurochemistry, 2004-10, Vol.91 (2), p.413-422

2004

Volltextzugriff (PDF)

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Molecular neurodegeneration, 2010-06, Vol.5 (1), p.26-26, Article 26

2010

Volltextzugriff (PDF)

Entretiens sur Le temps

2021

Volltextzugriff (PDF)

1 – 25 von 631

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(474)
Mit Volltextzugriff
(561)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Dynamical System Modulation for Robot Learning via Kinesthetic Demonstrations

Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity

Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease

Genome-Wide Expression Profiling of Human Blood Reveals Biomarkers for Huntington's Disease

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

Adhesive arachnoiditis following inadvertent epidural injection of 2% chlorhexidine in 70% alcohol - partial recovery over the ensuing eight years

Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease

Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease

Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse

Impaired Cerebrovascular Reactivity in Huntington's Disease

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG

Nuclear and Neuropil Aggregates in Huntington's Disease: Relationship to Neuropathology

KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients

Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

Cysteine Oxidation within N-terminal Mutant Huntingtin Promotes Oligomerization and Delays Clearance of Soluble Protein

The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease

Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease

A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

The CREST-E study of creatine for Huntington disease: A randomized controlled trial

Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation

The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Entretiens sur Le temps

Suchergebnisse filtern